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Burden of end-stage renal disease among indigenous peoples in enous” group; they are believed to have arrived from
Australia and New Zealand. Rates of end-stage renal disease Polynesia in the 10th century and number 14.5% of the
(ESRD) among indigenous people in Australia and New total NZ population of 3.8 million [2]. In more recentZealand are considerebly higher than the non-indigenous pop-
times migrants have arrived from other Pacific Islandsulation. This trend, apparent for several years, is described
in the region (Samoa, Cook Islands, Tonga, Niue, Fiji,here using data from the Australia & New Zealand Dialysis
and Transplant (ANZDATA) Registry. The average age at Tokelau), and these now number 5.6% of the New Zea-
start of renal replacement therapy (RRT) is approximately 10 land population. They are included here because of their
years less than non-indigenous people. Among those starting
similar origin and health profiles to the Maori group.RRT, rates of “diabetic nephropathy” are higher among indige-
In both countries, the health profile of indigenousnous patients, reflecting higher rates of diabetes. The increased
burden of illness extends to coronary artery disease and chronic groups has been poor, with life expectancies considerably
lung disease, which are present at rates 1.5 to 2 times non- less than nonindigenous groups. Other issues associated
indigenous rates. Once dialysis treatment has commenced, in- with indigenous status in both Australia and New
digenous people are less likely to be placed on the active
Zealand are characteristic of populations suffering fromcadaveric transplant waiting list, and less likely to receive a
the crisis of social, cultural and environmental transition,graft. Overall mortality outcomes are poorer for indigenous
patients overall, and for each RRT modality. These outcomes and include high birth rates, poor nutrition, poor educa-
are not simply due to increased frequency of co-morbid illness: tion, high rates of unemployment, tobacco use, alcohol
for indigenous people receiving dialysis treatment the mortality use, and poverty, and overall low socioeconomic status.
rate adjusted for age and gender is around 11⁄2 times the non-
indigenous rate. These data are consistent with studies showing
increased rates of markers of early renal disease (in particular END-STAGE RENAL DISEASE INCIDENCEalbuminuria) among both Australian and New Zealand indige-
nous groups, and reflect a broader health profile marked by The incidence of end-stage renal disease (ESRD) among
high rates of diabetes, cardiovascular disease and chronic lung all groups (including non-indigenous) has risen steadily
disease. Addressing these issues is a major challenge for health over time, but the excess among indigenous groups has
care providers in these regions.
remained (Fig. 1). These differences become even more
dramatic when age-adjusted (about 1.6 times higher [3]),
as the ages of indigenous people commencing ESRD
Indigenous peoples from Australia and New Zealand
treatment are substantially younger than non-indigenous
are comprised of several ethnically distinct groups. Ab-
(Table 1).original Australians are believed to have arrived in Aus-
These incidence rates are not constant across differenttralia 40 to 50,000 years ago, and currently number around
areas; in Australia rates of ESRD among Aboriginal400,000 (2% of the overall population) [1]. The other
people vary widely from levels similar to non-AboriginalAustralian indigenous group is Torres Strait Islanders
rates in more urbanized areas to rates in excess of 1000/(TSI), who are of Melanesian origin and comprise around
106/year in remote areas [4]. The areas of excess rates11% of the Australian indigenous population. For rea-
can also be characterized by poorer socioeconomic indi-sons of small numbers, they are considered with Aborigi-
ces and access to health services as well as geography [5].nal Australians here.
The etiology of renal disease among indigenous peopleIn New Zealand, Maori are considered the first “indig-
in Australia and New Zealand differs from the non-
indigenous group. Rates of diabetic nephropathy are
much higher especially among Maori (Table 1). HowKey words: Aboriginal Australians, Torres Strait Islanders, Maori, health
profile, dialysis, transplantation, Registry data. reliable this rate is remains unclear; overall biopsy rates
for ESRD cases attributed to “Diabetic nephropathy” 2003 by the International Society of Nephrology
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Fig. 1. Incident end-stage renal disease (ESRD)
rates for indigenous people for Australia and
New Zealand (data are not age-adjusted) [6].
Table 1. Distribution of gender, age and native renal disease by ESRD TREATMENT
indigenous group for new ESRD patients treated in
Australia and New Zealand 1991–2001 [6] In theory all modalities of treatment are available
throughout Australia and New Zealand. There is varia-Age at ESRD Diabetic
tion in practice patterns, however. Around 60% of MaoriMale entry median nephropathy
Group % (IQR) % and Pacific Islander people receive treatment by perito-
Non-indigenous 59 60 (45–69) 17 neal dialysis, consistent with practice for the non-indige-
Indigenous Australians 43 48 (40–57) 47 nous groups in the North Island of New Zealand. For
Maori 57 44 (45–61) 63
Aboriginal/Torres Strait Islanders, crude figures suggestPacific Islanders 48 51 (40–61) 55
they are less likely to be treated with peritoneal dialysisAbbreviations are: ESRD, end-stage renal disease; IQR, interquartile range.
[odds ratio (OR) 0.77, 95% CI, 0.67 to 0.88], but this is
due to differences in PD prevalence between Australia
states, and when adjusted for this there is no difference
are around 20% in non-indigenous and Aboriginal Aus- (OR 1.0, 95% CI, 0.9 to 1.2; Mantel-Haenszel adjustment
tralians and as low 5% for Maori and 8% for Pacific by state) [6].
Islanders, suggesting that an opportunity for reporting Access to transplantation is lower for indigenous groups,
bias may arise. and reflects differences throughout the process. The pro-
The higher rates of comorbidities present in indige- portion of patients 15 to 65 years receiving dialysis treat-
nous people starting ESRD treatment reflect the poorer ment who have been listed (at least once) on the active
general health of these groups. For example, age specific waiting list for renal transplantation is lower among
rates of coronary artery disease and lung disease are 1.5 Maori and Aboriginal patients (31% for Australian Ab-
to 2 times higher among indigenous ESRD patients [6]. original, 34% for Maori and Pacific Islanders, compared
This is consistent with the findings in the non-ESRD to 59% in non-indigenous groups, all comparisons P 
indigenous community, where ischemic heart disease and 0.0001). These differences are not explained by differ-
chronic lung disease are responsible for substantial pro- ences in prevalence of comorbidities, since, when strati-
portions of the excess morbidity and mortality in these fied by comorbid condition the differences persist [6].
groups. When all comorbid conditions and age category and gen-
The greatest excess comorbidity among ESRD en- der are included in a multiple logistic regression analysis,
trants, however, occurs for diabetes (Fig. 2). This is due the OR for listing on the active list for indigenous people
to type 2 diabetes, and reflects the burden of this disease compared to non-indigenous is 0.48 (95% CI, 0.42 to
in the underlying populations, where excess rates of dia- 0.54; P  0.0001).
betes have been well documented among Aboriginal Once on the active transplant waiting list, indigenous
people are less likely to receive a graft, with similar ratesAustralians [7] and Maori [8].
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Fig. 2. Proportion of ESRD entrants in Aus-
tralia and New Zealand 1991 to 2001 with dia-
betes (at time of ESRD entry) [6].
by lower rates of transplantation, as outcomes for each
modality of treatment are worse for indigenous than
non-indigenous groups.
For those on dialysis treatment, mortality rates for the
Aboriginal Australia and Maori groups are significantly
higher. This difference applies when adjusted for age cate-
gory, gender and comorbidity; hazard ratios (HR) for death
on dialysis relative to the non-indigenous group are 1.41
(95% CI, 1.24 to 1.60; P  0.001) for Aboriginal, (95%
CI, 1.30 to 1.68; P  0.001) for Maori and 0.80 (95%
CI, 0.65 to 1.00; P  0.05) among Pacific Islanders [6].
For transplant recipients, there is a similar excess of
mortality rates as well as of graft loss (Table 2). Never-
theless, there is a clear mortality benefit when graft recip-Fig. 3. Survival on renal replacement therapy (irrespective of HD, PD
ients are compared with those on the waiting list (Fig. 4).or transplant) by race adjusted for age, gender, diabetes, cardiac and
pulmonary disease [6].
DISCUSSION
The excess of ESRD among indigenous groups in Aus-among the indigenous groups (overall OR for receiving
tralia and New Zealand is striking, and has increasedgraft once on waiting list for indigenous person 0.35,
95% CI, 0.29 to 0.43; P 0.0001). Factors contributing to greatly over the past decade. Is some of this increase
this statistic include lower rates of living related or unre- due to ascertainment bias? Although a possible factor
lated transplants for Aboriginal (but not Maori of Pacific in years past, this is unlikely to apply to the statistics
Islander) people. For those on the cadaveric waiting list, quoted here for the past decade. During that time virtu-
indigenous people receive fewer grafts allocated on the ally every community has had access to a health clinic
basis of matching rather than waiting time (OR for re- and ESRD treatment services have been provided in all
ceiving cadaveric graft with 0 or 1 mismatches is 0.69, states and territories of Australia and New Zealand.
95% CI, 0.47 to 0.98; P  0.03 for indigenous vs. non- Increased uptake rates of renal replacement therapy are
indigenous people). possible, but the age of almost all indigenous ESRD
patients is such that they would not be affected by the
ESRD OUTCOMES recent changes in propensity to dialyze the elderly. The
absolute size of this epidemic of ESRD ultimately re-Overall mortality rates among those receiving renal
mains unmeasured, because there are no accurate datareplacement therapy are higher in indigenous than non-
about the numbers of people dying due to untreatedindigenous patients, even when adjusted for traditional
co-morbidities (Fig. 3). This is not due to confounding ESRD. Death certificates unfortunately are often inade-
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Table 2. Graft survival and patient survival for transplants in Australia and New Zealand 1991–2000, by indigenous racial group
Graft survival, % [95% CI] Patient survival, % [95% CI]
Group 1 year 5 years 1 year 5 years
Non-indigenous 88.6 [87.7–89.5] 77.4 [76.1–78.8] 97.5 [96.9–98.0] 93.1 [91.8–94.2]
Aboriginal Australian 84.5 [77.9–89.3] 48.7 [38.4–58.3] 93.5 [86.1–97.1] 86.4 [75.5–92.7]
Maori 83.3 [75.9–88.6] 58.8 [47.7–68.2] 97.9 [91.7–99.5] 87.9 [71.2–95.0]
Pacific Islander 83.1 [73.4–89.5] 41.6 [26.4–56.2] 96.3 [85.7–99.1] 96.3 [85.7–99.1]
rate downward relative to previous years. Although the
variation in absolute rates between communities can be
considerable, in communities in the Northern Territory
of Australia the pattern of increasing rates is similar
between various communities [17]. One can speculate
this is related to different phases of the transition be-
tween traditional and “Western” lifestyle, depending on
the time of exposure to these “Western” influences.
The underlying causes of the excess ESRD rates among
indigenous groups have been well studied. A number of
factors have been associated with renal disease in addi-
tion to the diabetes. Low birth weight [18], reduced renal
volume in childhood [19], occurrence of childhood post-
streptococcal glomerulonephritis [20], obesity and insu-
lin resistance, alcohol use, repeated acute bacterial infec-
tions and hypertension [9] have all been implicated as
Fig. 4. Hazard ratio for mortality after cadaveric transplantation com- factors contributing to the high incidence rates.
pared to those on the active waiting list for indigenous people only. Although the data here describe ESRD treated in Aus-
Statistics are for the years 1991 to 2000; Cox regression with discrete
tralia and New Zealand, there is some evidence this in-time varying covariates, adjusted for age category and gender.
crease in rates among indigenous people extends through-
out the Oceania region. High rates of ESRD have been
described in American Samoa [21] and Saipan (S. Abidi,
quate in attributing causality to chronic illnesses such as unpublished data).
renal disease and diabetes. Reducing the effect of this burden will require action
Not only do these indigenous groups suffer greatly on several fronts. Improvement of survival rates on renal
increased rates of ESRD, but the mortality rates on replacement therapy will require meticulous attention
treatment are considerably higher, further emphasizing to cardiovascular risk factors. Transplantation brings the
the burden of disease this imposes. Consistent with the need for judicious balancing of the requirement for im-
ESRD rates is widespread early renal disease seen in munosuppression against susceptibility to infection in a
several communities where detailed studies have been person more likely to have diabetes, coronary artery dis-
performed, in particular showing high rates of albumin- ease or bronchiectasis, and who is exposed to an environ-
uria [8–12]. As well as denoting increased risk of progres- ment marked by crowding and repetitive bacterial infec-
sion to renal failure [13], in this environment albuminuria tions. A further burden on patients receiving hemodialy-
marks an increased risk of both cardiovascular and all- sis therapy is that of distance. Although less of an issue
cause mortality [14, 15]. in New Zealand, in Australia many of the ESRD patients
Although there is the appearance of a “plateau” in live in areas considerable distances from hemodialysis
the rates among Aboriginal Australians in Figure 1, this facilities, and treatment thus involves considerable dis-
needs to be seen in the context of a rapid increase in location away from social supports with all its conse-
the proportion of the Australian population counted by quences on family, employment, and the community. To
the Census as Aboriginal. This increase is in excess of try and address this dilemma, several units have exam-
that accounted for by birth rates. An increased propen- ined the provision of dialysis facilities away from large
sity to self-identify as Aboriginal is the cause, seen partic- population centers. One approach is to utilize peritoneal
ularly in areas around the capital cities [16]. As rates of dialysis. Although this may seem an ideal approach, it has
renal disease are lower among indigenous people in these not been utilized extensively in this group of Aboriginal
Australians. Rates of PD are much higher in New Zea-areas [4], this will bias the overall Australian indigenous
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